Mirikizumab + Tirzepatide for Crohn's Disease
(COMMIT-CD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.The maximum duration of this study is up to 61 weeks.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, it mentions that participants should have had an inadequate response to or intolerance to certain conventional or advanced therapies for Crohn's Disease.
What safety data exists for Mirikizumab and Tirzepatide in humans?
How is the drug combination of Mirikizumab and Tirzepatide unique for treating Crohn's disease?
The combination of Mirikizumab and Tirzepatide for Crohn's disease is unique because Mirikizumab is a monoclonal antibody that targets interleukin-23, a protein involved in inflammation, and has shown effectiveness in other inflammatory conditions like psoriasis and ulcerative colitis. This combination may offer a novel approach by potentially addressing both inflammation and metabolic aspects of Crohn's disease, although Tirzepatide's role in this context is less clear from the available data.12367
What data supports the effectiveness of the drug Mirikizumab for Crohn's Disease?
Who Is on the Research Team?
Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
Adults with moderate to severe Crohn's Disease who are also overweight or obese can join this trial. Specific details about what makes someone eligible or not weren't provided, but typically participants must meet certain health standards and not have conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive mirikizumab and placebo or mirikizumab with tirzepatide for Crohn's Disease and obesity or overweight
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Mirikizumab
- Tirzepatide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University